Küchenmeister U, Kirchner R, Mellert J, Klautke G, Mücke R, Hopt U T, Fietkau R
Klinik und Poliklinik für Strahlentherapie, Universität Rostock.
Strahlenther Onkol. 2000 Dec;176(12):560-6. doi: 10.1007/pl00002325.
In locally advanced rectal cancer tumor-negative margins often cannot be obtained by surgery alone. Nevertheless only patients with complete tumor resection can be cured. Due to the poor prognosis of patients with R1/R2 resection the "Deutsche Krebsgesellschaft" recommends concurrent preoperative radiochemotherapy for patients with locally advanced rectal cancer.
Between May 1997 and November 1999 22 patients were treated with preoperative radiochemotherapy. A total dose of 45 Gy with a small-volume boost of 5.4 Gy was delivered in conventional fractionation (single dose 1.8 Gy). On days 1 to 5 and 29 to 33 patients received concurrently 5-fluorouracil (5-FU) as continuous infusion of 1,000 mg/m2. If there was any sign of cardiac toxicity chemotherapy was changed to 5-FU/folinic acid or ralitrexed.
Surgery following radiochemotherapy was performed in 19/22 patients. Resections with negative margins were achieved in 16/19 (84%) patients. Sphincter-conserving surgery was possible in 9/19 (47%) patients. A downstaging of at least 1 T category was found in 12/19 (63%) patients. With a median follow-up of 16 months no locoregional recurrences occurred in patients who underwent surgery. Two-year disease-free survival of resected patients is 62%, 2-year overall survival is 89%, of the whole population 76%.
Preoperative radiochemotherapy followed by surgery is able to achieve clear resection margins in more than 70% of patients with locally advanced rectal cancer and may improve the rate of sphincter-conserving surgery.
在局部晚期直肠癌中,仅通过手术往往无法获得肿瘤阴性切缘。然而,只有肿瘤完全切除的患者才能治愈。鉴于R1/R2切除患者的预后较差,“德国癌症协会”建议对局部晚期直肠癌患者进行术前同步放化疗。
1997年5月至1999年11月期间,22例患者接受了术前放化疗。采用常规分割方式(单次剂量1.8 Gy)给予总剂量45 Gy,并对小体积区域追加5.4 Gy的放疗剂量。在第1至5天和第29至33天,患者同时接受5-氟尿嘧啶(5-FU)持续静脉输注,剂量为1000 mg/m²。若出现任何心脏毒性迹象,则将化疗方案改为5-FU/亚叶酸或雷替曲塞。
22例患者中有19例在放化疗后接受了手术。19例患者中有16例(84%)实现了切缘阴性切除。19例患者中有9例(47%)可行保肛手术。19例患者中有12例(63%)至少实现了1个T分期的降期。中位随访16个月,接受手术的患者未发生局部区域复发。切除患者的2年无病生存率为62%,2年总生存率为89%,总体人群的2年总生存率为76%。
术前放化疗后行手术能够使超过70%的局部晚期直肠癌患者获得切缘阴性切除,且可能提高保肛手术率。